Tierra Biosciences, a California-based startup, has secured $11.4 million in a Series A round led by Material Impact. The company is developing AI-guided cell-free technology to revolutionize protein synthesis, reducing manufacturing time from months to weeks. This investment aims to pioneer protein synthesis and leverage AI breakthroughs for genomic sequencing.
Being able to generate large datasets has never been more important in biology given the potential of AI. Better synthesis technologies are essential. @fiftyyears company @tierrabio has $11m more to pioneer protein synthesis. More: https://t.co/V36RiWHRkK https://t.co/TYMAOqf9q6
We are delighted to announce our #investment in @TierraBio, the company behind the world’s first platform for producing proteins with predictive AI-guided cell-free technology. https://t.co/88aecd90BG #synbio #GenAI #funding #VC
.@tierrabio -a California-based startup developing AI-guided cell-free technology to enable high-throughput custom protein synthesis—has closed an $11.4m Series A round led by @materialimpact https://t.co/yw7nn8pKYX
By using cell-free technology, Tierra Biosciences is able to cut down protein manufacturing from months to weeks and enable customers to order proteins online. https://t.co/tPYlAdshUO
Tierra Biosciences nabs $11 million to create new AI-guided proteins https://t.co/0ZiBboLrhz
🧬 I'm so excited for everything we're gonna get from the plummeting costs of sequencing a human genome, combined with these breakthroughs in AI, and that's why we led this early investment in Nucleus. https://t.co/0asHO5UE2Y